Cover Image

Autoimmune Hepatitis: a review of established and evolving treatments

Autoimmune hepatitis (AIH) is a necroinflammatory liver disease commonly presenting with a fluctuating course of activity, presence of circulating autoantibodies, hyperglobulinemia of IgG, and/or response to immunosuppressive drugs. However, the disease displays a considerable heterogeneity. No sing...

Full description

Saved in:
Bibliographic Details
Main Authors: Bischoff, Sebastian (Author) , Yesmembetov, Kakharman (Author) , Antoni, Christoph Helmer (Author) , Sollors, Janina (Author) , Evert, Matthias (Author) , Ebert, Matthias (Author) , Teufel, Andreas (Author)
Format: Article (Journal)
Language:English
Published: September 2020
In: Journal of gastrointestinal and liver diseases
Year: 2020, Volume: 29, Issue: 3, Pages: 429-443
ISSN:1842-1121
DOI:10.15403/jgld-2667
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.15403/jgld-2667
Verlag, lizenzpflichtig, Volltext: https://jgld.ro/jgld/index.php/jgld/article/view/2667
Get full text
Author Notes:Sebastian Bischoff, Kakharman Yesmembetov, Christoph Antoni, Janina Sollors, Matthias Evert, Matthias Ebert, Andreas Teufel
Description
Summary:Autoimmune hepatitis (AIH) is a necroinflammatory liver disease commonly presenting with a fluctuating course of activity, presence of circulating autoantibodies, hyperglobulinemia of IgG, and/or response to immunosuppressive drugs. However, the disease displays a considerable heterogeneity. No single clinical or biochemical test may establish diagnosis of AIH. Thus, diagnosis still requires extensive clinical evaluation and experience. Prednisolone and azathioprine are considered standard treatment leading to remission in most patients. However, this standard treatment may not be effective in some patients or not be feasible due to one of these drugs. Over the past two decades additional immunosuppressant drugs for the treatment of AIH have been evaluated and have significantly extended the therapeutic spectrum. Among those novel drugs are mycophenolate mofetil, tacrolimus, everolimus, 6-mercaptopurine, infliximab, rituximab and several others. In this review we summarize the current standard of therapy but also efforts of providing novel therapeutic strategies to AIH patients.
Item Description:Gesehen am 01.12.2025
Physical Description:Online Resource
ISSN:1842-1121
DOI:10.15403/jgld-2667

Similar Items